DVAX icon

Dynavax Technologies

10.10 USD
+0.17
1.71%
At close Updated Oct 16, 10:00 AM EDT
1 day
1.71%
5 days
-2.13%
1 month
4.12%
3 months
-5.34%
6 months
-5.16%
Year to date
-21.71%
1 year
-8.43%
5 years
127.48%
10 years
-57.93%
 

About: Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Employees: 405

0
Funds holding %
of 7,494 funds
0
Analysts bullish %
of 1 analysts
Positive news %
of articles
Price charts implemented using Lightweight Charts™